How You Could Double Your Money at Least 6 TIMES This Year

On May 19, iconic growth investor Louis Navellier will reveal how his powerful quant-based stock system could accelerate your wealth and help fund your retirement.

Wed, May 19 at 4:00PM ET
 
 
 
 

6 Pharmaceutical Stocks to Buy Now

The grades of six pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

GW Pharmaceuticals PLC Sponsored ADR (GWPH) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

This week, Watson Pharmaceuticals (WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Lipocine, Inc. (LPCN) earns a B this week, jumping up from last week’s grade of C. Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

The rating of Cardiome Pharma (CRME) moves up this week, rising from a C to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. Shares of the stock have been trading at an exceptionally rapid pace, up fourfold from the week prior. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This week, AbbVie, Inc.’s (ABBV) ratings are up from a C last week to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/03/6-pharmaceutical-stocks-to-buy-now-path-gwph-wpi-2/.

©2021 InvestorPlace Media, LLC